Sorry, you need to enable JavaScript to visit this website.
Logo

IgA NEPHROPATHY TREATMENT EXPLORATION

Advancement is needed in the treatment of IgA Nephropathy

A better understanding of the pathophysiology of IgA Nephropathy and relevant clinical endpoints may help provide targets for future treatment exploration.

Learn about an FDA-approved treatment option that may help manage IgaN

GO NOW

Identifying surrogate and functional endpoints is key to
evaluating new therapeutic options for IgA Nephropathy.5,22,23

kidney-iga-nephropathy-treatment

eGFR

A functional endpoint that denotes deteriorating kidney function24

eGFR is considered the most useful overall measure of kidney function5,23

A reduction in eGFR is associated directly with a worse renal prognosis in patients with IgA Nephropathy23,24

proteinuira-test-iga-nephropathy

Proteinuria

A surrogate endpoint that serves as a sign of kidney injury22

While proteinuria levels are variable and can fluctuate episodically, they are a useful indicator in IgA Nephropathy21,25

There is a strong and consistent relationship between the level and duration of proteinuria and loss of kidney function in patients with IgA Nephropathy21,25

Sign up to be the first to receive all the latest IgA Nephropathy news and updates

Stay connected with Calliditas. 

kedney-information-iga-nephropathy
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
One or more fields have an error. Please check and try again.

IgA=immunoglobulin A; IgAN=immunoglobulin A Nephropathy; MOD=mechanism of disease.

References: 1. Barratt J, Rovin BH, Cattran D, et al. Kidney Int Rep. 2020;5(20):1620-1624. doi:10.1016/j.ekir.2020.08.009

2. Hastings MC, Bursac Z, Julian BA, et al. Kidney Int Rep. 2017;3(1):99-104. doi:10.1016/j.ekir.2017.08.008

3. Schena FP. Am J Med. 1990;89(2):209-215. doi:10.1016/0002-9343(90)90300-3

4. Barratt J, Feehally J. Semin Nephrol. 2011;31(4):349-360. doi:10.1016/j.semnephrol.2011.06.006

5. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012;2(suppl 2):259-274.

6. IgA Nephropathy Foundation of America, Inc. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy. https://nkf.egnyte.com/dl/aHGCS6tPNM/?. Accessed August 18, 2021.

7. Penfold RS, Prendecki M, McAdoo S, Tam FWK. Int J Nephrol Renovasc Dis. 2018;11:137-148. doi:10.2147/IJNRD.S129227

8. Arroyo AH, Bomback AS, Butler B, et al. Clin Nephrol. 2015;84(3):145-155. doi:10.5414/CN108556

9. Rauen T, Wied S, Fitzner C, et al; for the STOP-IgAN Investigators. Kidney Int Supp. 2020;98(4):1044-1052. doi:10.1016/j.kint.2020.04.046

10. Lafayette RA, Kelepouris E. Am J Nephrol. 2018;47(suppl 1):43-52. doi:10.1159/000481636

11. United States Renal Data System (USRDS). 2018 USRDS Annual Data Report. Vol 2. 2018; chap 9. Accessed April 7, 2021. https://usrds.org/media/1734/v2_c09_esrd_costs_18_usrds.pdf.

12. Golestaneh L, Alvarez PJ, Reaven N, et al. Am J Manag Care. 2017;23(10 Suppl):S163-S172.

13. Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R. Am J Kidney Dis. 2013;62(5):883-890. doi:10.1053/j.ajkd.2013.04.019

14. Ponticelli C, Glassock RJ. Clin J Am Soc Nephrol. 2010;5(12):2363-2372. doi:10.2215/CJN.06720810

15. Ponticelli C, Traversi L, Banfi G. Pediatr Transplant. 2004:8(4):334-338. doi:10.1111/j.1399-3046.2004.00177.x

16. Kiryluk K, Novak J. J Clin Invest. 2014;124(6):2325-2332. doi:10.1172/JCI74475

17. Yeo SC, Cheung CK, Barratt J. Pediatr Nephrol. 2018;33(5):763-777. doi:10.1007/s00467-017-3699-z

18. Jung C, Hugot JP, Barreau F. Int J Inflam. Published online September 19, 2010. doi:10.4061/2010/823710

19. Barratt J, Smith AC, Feehally J. Nephrology (Carlton). 2007;12(3):275-284. doi:10.1111/j.1440-1797.2007.00797.x

20. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. Kidney Int. 2012;81(9):833-843. doi:10.1038/ki.2011.501

21. Lafayette RA. Transl Res. 2014;163(1):3-7. doi:10.1016/j.trasl.2013.08.007

22. Thompson A, Carroll K, Inker LA, et al. Clin J Am Soc Nephrol. 2019;14(3):469-481. doi:10.2215/CJN.08600718

23. Ibrahim A, Garg AX, Knoll GA, Akbari A, White CA. Am J Transplant. 2013;13(3):708-713. doi:10.1111/ajt.12050

24. Levey AS, Gansevoort RT, Coresh J, et al. Am J Kidney Dis. 2020;75(1):84-104. doi:10.1053/j.ajkd.2019.06.009

25. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. Nephrol Dial Transplant. 2009;24(10):3068-3074. doi:10.1093/ndt/gfp273

26. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. J Am Soc Nephrol. 2007;18(2):637-645. doi:10.1681/ASN.2006070738